All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Primary overall survival (OS) analysis of the phase III ZUMA-7 trial shows a statistically significant improvement in OS for axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) as initial treatment in adult patients with relapsed/refractory large B-cell lymphoma (LBCL) within 12 months of first-line therapy completion. Traditionally, SOC has been a multi-step process involving a salvage combination chemoimmunotherapy regimen, followed by high-dose therapy and stem cell transplant in those who respond to salvage chemotherapy.1
ZUMA-7 (NCT03391466) is a randomized, open-label, global phase III trial evaluating the safety and efficacy of axi-cel versus SOC for the initial treatment of adult patients with relapsed/refractory LBCL. The primary endpoint is event-free survival, with key secondary endpoints including objective response rate and OS. Thus far, axi-cel has demonstrated favorable efficacy profiles along with acceptable safety. Data from this pivotal trial has already led to regulatory approvals from the U.S. Food and Drug Administration (FDA) and the European Commission.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox